Works matching IS 01676997 AND DT 2015 AND VI 33 AND IP 2

Results: 32

Pharmacokinetic study of aldoxorubicin in patients with solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 341, doi. 10.1007/s10637-014-0183-5

By:

Mita, Monica;
Natale, Ronald;
Wolin, Edward;
Laabs, Brenda;
Dinh, Hillary;
Wieland, Scott;
Levitt, Daniel;
Mita, Alain

Publication type:

Article

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.

Published in:

2015

By:

Sasaki, Yasutsuna;
Miwa, Keisuke;
Yamashita, Keishi;
Sunakawa, Yu;
Shimada, Ken;
Ishida, Hiroo;
Hasegawa, Kosei;
Fujiwara, Keiichi;
Kodaira, Makoto;
Fujiwara, Yasuhiro;
Namiki, Masayuki;
Matsuda, Minami;
Takeuchi, Yutaka;
Katsumata, Noriyuki

Publication type:

Journal Article

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

Published in:

2015

By:

Rodón, Jordi;
Carducci, Michael;
Sepulveda-Sánchez, Juan;
Azaro, Analía;
Calvo, Emiliano;
Seoane, Joan;
Braña, Irene;
Sicart, Elisabet;
Gueorguieva, Ivelina;
Cleverly, Ann;
Pillay, N.;
Desaiah, Durisala;
Estrem, Shawn;
Paz-Ares, Luis;
Holdhoff, Matthias;
Blakeley, Jaishri;
Lahn, Michael;
Baselga, Jose

Publication type:

Journal Article

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 357, doi. 10.1007/s10637-014-0192-4

By:

Rodón, Jordi;
Carducci, Michael;
Sepulveda-Sánchez, Juan;
Azaro, Analía;
Calvo, Emiliano;
Seoane, Joan;
Braña, Irene;
Sicart, Elisabet;
Gueorguieva, Ivelina;
Cleverly, Ann;
Pillay, N.;
Desaiah, Durisala;
Estrem, Shawn;
Paz-Ares, Luis;
Holdhoff, Matthias;
Blakeley, Jaishri;
Lahn, Michael;
Baselga, Jose

Publication type:

Article

A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 480, doi. 10.1007/s10637-014-0189-z

By:

Alumkal, Joshi;
Slottke, Rachel;
Schwartzman, Jacob;
Cherala, Ganesh;
Munar, Myrna;
Graff, Julie;
Beer, Tomasz;
Ryan, Christopher;
Koop, Dennis;
Gibbs, Angela;
Gao, Lina;
Flamiatos, Jason;
Tucker, Erin;
Kleinschmidt, Richard;
Mori, Motomi

Publication type:

Article

PBI-05204, a supercritical CO extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 271, doi. 10.1007/s10637-014-0190-6

By:

Pan, Yong;
Rhea, Patrea;
Tan, Lin;
Cartwright, Carrie;
Lee, Ho-Jeong;
Ravoori, Murali;
Addington, Crandell;
Gagea, Mihai;
Kundra, Vikas;
Kim, Sun-Jin;
Newman, Robert;
Yang, Peiying

Publication type:

Article

Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 349, doi. 10.1007/s10637-014-0191-5

By:

Dickson, Mark;
Gordon, Michael;
Edelman, Gerald;
Bendell, Johanna;
Kudchadkar, Ragini;
LoRusso, Patricia;
Johnston, Stuart;
Clary, Douglas;
Schwartz, Gary

Publication type:

Article

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 332, doi. 10.1007/s10637-014-0180-8

By:

Sasaki, Yasutsuna;
Miwa, Keisuke;
Yamashita, Keishi;
Sunakawa, Yu;
Shimada, Ken;
Ishida, Hiroo;
Hasegawa, Kosei;
Fujiwara, Keiichi;
Kodaira, Makoto;
Fujiwara, Yasuhiro;
Namiki, Masayuki;
Matsuda, Minami;
Takeuchi, Yutaka;
Katsumata, Noriyuki

Publication type:

Article

A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 371, doi. 10.1007/s10637-014-0194-2

By:

Odenike, Olatoyosi;
Halpern, Anna;
Godley, Lucy;
Madzo, Jozef;
Karrison, Theodore;
Green, Margaret;
Fulton, Noreen;
Mattison, Ryan;
Yee, Karen.;
Bennett, Meghan;
Koval, Gregory;
Malnassy, Gregory;
Larson, Richard;
Ratain, Mark;
Stock, Wendy

Publication type:

Article

Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 510, doi. 10.1007/s10637-014-0195-1

By:

Yoneshima, Yasuto;
Okamoto, Isamu;
Arimura-Omori, Masako;
Kimura, Shinichi;
Hidaka-Fujimoto, Noriko;
Iwama, Eiji;
Harada, Taishi;
Takayama, Koichi;
Nakanishi, Yoichi

Publication type:

Article

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 380, doi. 10.1007/s10637-014-0196-0

By:

Fujisaka, Yasuhito;
Kurata, Takayasu;
Tanaka, Kaoru;
Kudo, Toshihiro;
Okamoto, Kunio;
Tsurutani, Junji;
Kaneda, Hiroyasu;
Okamoto, Isamu;
Namiki, Masayuki;
Kitamura, Chifumi;
Nakagawa, Kazuhiko

Publication type:

Article

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 490, doi. 10.1007/s10637-014-0197-z

By:

Matsuyama, Masato;
Ishii, H.;
Furuse, J.;
Ohkawa, S.;
Maguchi, H.;
Mizuno, N.;
Yamaguchi, T.;
Ioka, T.;
Ajiki, T.;
Ikeda, M.;
Hakamada, K.;
Yamamoto, M.;
Yamaue, H.;
Eguchi, K.;
Ichikawa, W.;
Miyazaki, M.;
Ohashi, Y.;
Sasaki, Y.

Publication type:

Article

Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 389, doi. 10.1007/s10637-014-0198-y

By:

Tibes, R.;
McDonagh, K.;
Lekakis, L.;
Bogenberger, J.;
Kim, S.;
Frazer, N.;
Mohrland, S.;
Bassett, D.;
Garcia, R.;
Schroeder, K.;
Shanmugam, V.;
Carpten, J.;
Hagelstrom, R.;
Beaudry, C.;
Hoff, D.;
Shea, T.

Publication type:

Article

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 397, doi. 10.1007/s10637-014-0199-x

By:

Petrylak, Daniel;
Gandhi, Jitendra;
Clark, William;
Heath, Elisabeth;
Lin, Jianqing;
Oh, William;
Agus, David;
Carthon, Bradley;
Moran, Susan;
Kong, Ning;
Suri, Ajit;
Bargfrede, Michael;
Liu, Glenn

Publication type:

Article

Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 496, doi. 10.1007/s10637-014-0200-8

By:

Yau, Thomas;
Cheng, Paul;
Chan, Pierre;
Chen, Li;
Yuen, Jimmy;
Pang, Roberta;
Fan, Sheung;
Wheatley, Denys;
Poon, Ronnie

Publication type:

Article

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 409, doi. 10.1007/s10637-014-0201-7

By:

Dittrich, Christian;
Fridrik, Michael;
Koenigsberg, Robert;
Lee, Chooi;
Goeldner, Rainer-Georg;
Hilbert, James;
Greil, Richard

Publication type:

Article

Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 280, doi. 10.1007/s10637-014-0202-6

By:

Trendowski, Matthew;
Mitchell, Joan;
Corsette, Christine;
Acquafondata, Christopher;
Fondy, Thomas

Publication type:

Article

Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 290, doi. 10.1007/s10637-014-0203-5

By:

Trendowski, Matthew;
Mitchell, Joan;
Corsette, Christine;
Acquafondata, Christopher;
Fondy, Thomas

Publication type:

Article

The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 300, doi. 10.1007/s10637-015-0205-y

By:

Mathias, Trevor;
Natarajan, Karthika;
Shukla, Suneet;
Doshi, Kshama;
Singh, Zeba;
Ambudkar, Suresh;
Baer, Maria

Publication type:

Article

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 423, doi. 10.1007/s10637-015-0206-x

By:

Morschhauser, Franck;
Terriou, Louis;
Coiffier, Bertrand;
Bachy, Emmanuel;
Varga, Andrea;
Kloos, Ioana;
Lelièvre, Hélène;
Sarry, Anne-Laure;
Depil, Stéphane;
Ribrag, Vincent

Publication type:

Article

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 432, doi. 10.1007/s10637-015-0207-9

By:

Infante, Jeffrey;
Benhadji, Karim;
Dy, Grace;
Fetterly, Gerald;
Ma, Wen;
Bendell, Johanna;
Callies, Sophie;
Adjei, Alex

Publication type:

Article

Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 505, doi. 10.1007/s10637-015-0209-7

By:

Sanoff, Hanna;
Kim, Richard;
Ivanova, Anastasia;
Alistar, Angela;
McRee, Autumn;
O'Neil, Bert

Publication type:

Article

Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 310, doi. 10.1007/s10637-015-0210-1

By:

Lattanzio, Laura;
Tonissi, Federica;
Monteverde, Martino;
Vivenza, Daniela;
Russi, Elvio;
Milano, Gérard;
Merlano, Marco;
Lo Nigro, Cristiana

Publication type:

Article

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 440, doi. 10.1007/s10637-015-0211-0

By:

LoRusso, Patricia;
Goncalves, Priscila;
Casetta, Lindsay;
Carter, Judith;
Litwiler, Kevin;
Roseberry, Dale;
Rush, Selena;
Schreiber, Jennifer;
Simmons, Heidi;
Ptaszynski, Mieke;
Sausville, Edward

Publication type:

Article

Aptamers as a novel tool for diagnostics and therapy.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 513, doi. 10.1007/s10637-015-0213-y

By:

Kadioglu, Onat;
Malczyk, Anna;
Greten, Henry;
Efferth, Thomas

Publication type:

Article

Axitinib plasma pharmacokinetics and ethnic differences.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 521, doi. 10.1007/s10637-015-0214-x

By:

Chen, Ying;
Suzuki, Akiyuki;
Tortorici, Michael;
Garrett, May;
LaBadie, Robert;
Umeyama, Yoshiko;
Pithavala, Yazdi

Publication type:

Article

Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 450, doi. 10.1007/s10637-015-0217-7

By:

Higano, C.;
Berlin, J.;
Gordon, M.;
LoRusso, P.;
Tang, S.;
Dontabhaktuni, A.;
Schwartz, J.;
Cosaert, J.;
Mehnert, J.

Publication type:

Article

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 463, doi. 10.1007/s10637-015-0218-6

By:

Bendell, Johanna;
Kurkjian, Carla;
Infante, Jeffrey;
Bauer, Todd;
Burris, Howard;
Greco, F.;
Shih, Kent;
Thompson, Dana;
Lane, Cassie;
Finney, Lindsey;
Jones, Suzanne

Publication type:

Article

Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 472, doi. 10.1007/s10637-015-0219-5

By:

Joerger, M.;
Hess, D.;
Delmonte, A.;
Gallerani, E.;
Barbieri, P.;
Pace, S.;
Sessa, C.

Publication type:

Article

Acknowledgement of Reviewers 2013.

Published in:: Investigational New Drugs, 2015, v. 33, n. 2, p. 533, doi. 10.1007/s10637-015-0224-8
Publication type:: Article

Acknowledgement of Reviewers 2014.

Published in:: Investigational New Drugs, 2015, v. 33, n. 2, p. 536, doi. 10.1007/s10637-015-0225-7
Publication type:: Article

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 2, p. 321, doi. 10.1007/s10637-014-0171-9

By:

Peethambaram, P.;
Hartmann, L.;
Jonker, D.;
Jonge, M.;
Plummer, E.;
Martin, L.;
Konner, J.;
Marshall, J.;
Goss, G.;
Teslenko, V.;
Clemens, P.;
Cohen, L.;
Ahlers, C.;
Alland, L.

Publication type:

Article